Biocon announces a global partnership with Sandoz

To develop, manufacture and commercialise multiple biosimilars in immunology and oncology

Biocon and Sandoz, a Novartis division announced a global partnership to develop, manufacture and commercialise multiple biosimilars in immunology and oncology for patients worldwide.

Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products and will have a cost and profit share arrangement globally. Worldwide commercialisation responsibilities will be dividend and each company's strenths will be leveraged within specific geographies. Sandoz will lead commercialisation in North America and the EU while Biocon will lead commercialisation in Rest of the World.

 

Powered by Capital Market - Live News